Life Sciences Capital Aurora focuses on life sciences investment banking, offering private placements, corporate finance advisory, and public securities brokerage through Legent Clearing. This specialization aligns with the fundraising needs of biotech and pharma firms seeking capital, and its network of scientific advisors enhances due diligence and credibility for capital raises.

Cross-border Growth The Aurora KiwiSaver Scheme launch demonstrates cross-border product development and employee investment capabilities. This could create sales opportunities with NZ-based biotech firms expanding into APAC or with global life sciences companies seeking employee investment programs or cross-border fundraising options.

Scientific Network Aurora retains a network of scientific advisors and consultants, enabling sector-specific diligence and strategic input for complex financings and deals. In sales terms, this can be a differentiator when pitching capital raises, licensing strategies, or M&A advisory to life sciences clients.

Boutique Capital Partner As a lean boutique with three lines of business offering integrated solutions, Aurora can tailor capital markets packages for small-to-mid cap life sciences firms seeking private placements, advisory services, and brokerage support in one partner.

Growing Capacity Promotions in early 2022 reflect a growing deal execution capability and team depth, signaling readiness to take on more transactions and expand client coverage across the sector.